ENTHEON BIOMEDICAL CORP To Carry Out 1-for-10 Reverse Stock Split On March 1st, 2024
February 29th - $ENTHEON BIOMEDICAL CORP(ENTBF.US)$ is about to implement a 1-for-10 reverse stock split of shares. The shares will begin trading on a split-adjusted basis from March 1st, 2024.$ENTHEO
RBC Downgrades Nevro to Sector Perform, Cites Salesforce Turnaround
Psyched: Elon Musk Tweets About Psychedelics, Numinus Acquires Novamind, Colorado Gov. Signs MDMA Legalization Bill
Want to get the latest psychedelics industry news in your inbox every week? Subscribe to our Newsletter to become a Psychedelics Insider. Numinus (OTC:NUMIF) concluded its acquisition of Novamind (OTC
Largest Phase-1 DMT Study In The Netherlands, A Collaboration Between Entheon & Cybin
Cybin Inc. (NEO:CYBN) (NYSE:CYBE) announced that, through its wholly-owned subsidiary Cybin IRL Limited, It has entered into an agreement to acquire a Phase 1 N,N-dimethyltryptamine ("DMT") study from
Cybin to acquire DMT clinical study from Entheon Biomedical
Cybin (NYSE:CYBN) added ~8% in the pre-market Tuesday after the psychedelics-focused biopharma announced that its subsidiary Cybin IRL Limited agreed to acquire a Phase 1 N,N-dimethyltryptamine ("DMT"
Ehave Partners With Halugen Life Sciences To Create A Ketamine Precision Medicine Platform For Clinical Research
Ehave, Inc. (OTC:EHVVF) is a leading healthcare services and technology company focused on progressing psychedelics to therapeutics by engineering novel compounds and new treatment protocols for treat
Entheon Biomedical Announces Non-Brokered Private Placement Financing
Entheon Biomedical Corp. (OTCQB:ENTBF) announced a non-brokered private placement financing for up to 30,000,000 Units at a price of CDN$0.10 per unit, for gross proceeds of up to CDN$3,000,000. Each
Entheon Biomedical begins enrollment in phase 1 study of DMT for addiction disorders
Entheon Biomedical (OTCQB:ENTBF) said the first patient was enrolled in a phase 1 trial called EBRX-101 evaluating N, N-dimethyltryptamine (DMT) for addiction disorders. In the study — which is being
Entheon Biomedical gets recruitment underway in EBIQ-101 ketamine study
Entheon Biomedical (OTCQB:ENTBF) announces that recruitment has begun for the clinical research study with Heading Health to determine the electro-neurophysiologic effects of ketamine. EBIQ-101, an O
Entheon Biomedical Acquires Lobo Genetics, Inc. in Bid to Strengthen Screening and Treatment Evaluation Tech for Psychedelics
Image Provided by Wiki Commons Entheon Biomedical Corp. (OTCQB:ENTBF), the biotech research and development company focused on developing DMT-based treatments for addiction and substance use disorders
Psyched: Atai Life Sciences Hits Nasdaq, Canada To Fund Ketamine Trials, Mydecine Launches AI Drug-Discovery Platform
Atai Life Sciences (NASDAQ: ATAI) made its highly-anticipated Nasdaq debut on Friday. The Berlin-based company is joining an exclusive group of start-ups in the psychedelics sector to IPO this year o
No Data